A5013721914- Congenital Heart Disease Studies
- Aortic Disease and Treatment Approaches
- Cardiac Valve Diseases and Treatments
- Coronary Artery Anomalies
- Kawasaki Disease and Coronary Complications
- Cardiac Structural Anomalies and Repair
- Cardiovascular Syncope and Autonomic Disorders
- Cardiac pacing and defibrillation studies
- Cardiac Arrhythmias and Treatments
- Cardiovascular Issues in Pregnancy
- Infant Nutrition and Health
- Aortic aneurysm repair treatments
- Viral Infections and Immunology Research
- Tracheal and airway disorders
- Occupational Health and Safety in Workplaces
- Cardiomyopathy and Myosin Studies
- Cardiovascular Effects of Exercise
- Birth, Development, and Health
- Obesity, Physical Activity, Diet
Hospital Universitari Sant Joan de Reus
2010-2024
Sociedad Española de Cardiología
2019-2020
Kawasaki disease is a self-limiting acute vasculitis that affects small and medium-sized vessels, the most common cause of acquired heart in children our environment. Up to 25% untreated patients develop coronary aneurysms. It suspected an infectious agent may be trigger disease, but causative still unknown. Based on previous evidence, recommendations are proposed for diagnosis, treatment long-term management these patients, order unify criteria. The diagnosis must quick, based easy-to-use...
Los fármacos aprobados para el trastorno por déficit de atención con hiperactividad (TDAH) en España son: metilfenidato, lisdexanfetamina, atomoxetina y guanfacina. Debido a los efectos adversos cardiovasculares que pueden producir, principalmente aumento la presión arterial frecuencia cardíaca, su uso pacientes cardiopatías conocidas o no diagnosticadas puede ser controvertido. Realización un documento consenso Sociedad Española Cardiología Pediátrica Cardiopatías Congénitas (SECPCC)...
Approved drugs for attention deficit hyperactivity disorder (ADHD) in Spain are methylphenidate, lisdexamphetamine, atomoxetine and guanfacine. Due to adverse cardiovascular effects, mainly increased blood pressure heart rate, its use patients with known or undiagnosed disease may be controversial. To obtain a consensus document from the Spanish Society of Paediatric Cardiology Congenital Heart Diseases (SECPCC) experts other Agencies Societies as guide paediatric cardiologist physicians who...